MedTrace Logo

Chemotherapy With Anlotinib in Advanced Cervical Cancer

NCT04695535 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-01-05

No results posted yet for this study

Summary

STUDY HYPOTHESIS: The primary hypothesis is whether chemotherapy with Anlotinib improves overall survival in advanced cervical cancer.

TRIAL DESIGN: The study is a prospective, single-arm, observational clinical study. The study will be performed on an intent-to-treat population. All the enrolled patients received chemotherapy with Anlotinib.

PRIMARY ENDPOINT: Overall survival, defined as the observed length of life from entry into the study to death from any cause or the date of last contact.

Conditions

  • Uterine Cervical Neoplasms

Sponsors & Collaborators

  • Yang Shen

    lead OTHER

Principal Investigators

  • Yang Shen, MD · Zhongda Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2022-05-31
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695535 on ClinicalTrials.gov